Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

However, Recursion’s revenue fell short, reaching only $5.18 million compared to the expected $16.95 million. In another development, Recursion announced the registration of 7.1 million shares for ...

Microsoft no longer officially supports Windows 10, so do this if you want to keep using your older PC securely. Jason Chun is a CNET writer covering a range of topics in tech, home, wellness, finance ...

Shareholders of Noble Corporation plc (Symbol: NE) looking to boost their income beyond the stock's 7.1% annualized dividend yield can sell the January 2027 covered call at the $40 strike and collect ...

One analyst tracking the biotech upgraded her recommendation on its shares. She now believes that they rate a buy, rather than a hold. 10 stocks we like better than Recursion Pharmaceuticals › An ...